• The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix.
• The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing.
• SNGX has outlined a timeline of catalysts extending through the end of 2026.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash runway extending through the end of 2026, providing the resources needed to reach key clinical and regulatory inflection points across its diversified pipeline.

The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix, whose portfolio includes both late-stage therapeutics and vaccine candidates addressing high-unmet-need indications. With the recent financing in place, the company anticipates it will have sufficient capital to fund operations through multiple expected catalysts, including clinical updates, regulatory interactions and potential partnership opportunities. Soligenix noted that these moves were designed to reduce short-term funding pressure while preserving shareholder value amid ongoing progress in its core programs.

In the company’s announcement of the $7.5 million raise, Soligenix detailed that it issued approximately 5.56 million shares (or common-stock equivalents) and accompanying warrants at $1.35 per unit, generating gross proceeds of roughly $7.5 million before fees. The financing also involved amendments to prior warrants from 2023 and 2024, standardizing terms and improving future capital flexibility. The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing, ensuring operational continuity through expected value-creating milestones.

That stability is especially important given the potential embedded in Soligenix’s development pipeline. The company has outlined a timeline of catalysts extending through 2026 (https://ibn.fm/MtsAv). These include progress on its lead candidate HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”), SGX302 for psoriasis, SGX945 for Behçet’s disease, and SGX942 for oral mucositis in head and neck cancer. HyBryte, which has already achieved positive phase 3 results, remains the company’s anchor asset, with regulatory and commercialization preparations highlighted as near-term objectives.

Soligenix’s Public Health Solutions segment represents another key value stream. This division develops heat-stable vaccines and biodefense countermeasures using the company’s proprietary ThermoVax(R) platform. Its pipeline includes RiVax(R), a ricin toxin vaccine candidate that has been supported by multiple U.S. government contracts, as well as preclinical work on vaccine candidates for Ebola, Marburg and COVID–19. Collectively, these programs represent dual potential: near-term catalysts in rare-disease therapeutics and long-term value from government partnerships in biodefense.

With a financial runway now extending through 2026, Soligenix is strategically positioned to reach a convergence of data readouts, regulatory submissions and partnering opportunities without immediate dilution risk. For a development-stage biotech, this level of operational visibility provides a competitive advantage in both execution and investor confidence. The strengthened cash position also enables continued progress on clinical manufacturing, commercial readiness and global licensing initiatives, areas that typically require uninterrupted funding through regulatory transition phases.

Beyond the numbers, the company’s financial moves also suggest a broader maturation of its capital strategy. By aligning financing events with expected milestone timelines, Soligenix is signaling to the market that it intends to balance clinical progress with disciplined financial stewardship. This alignment between cash runway and value-driver cadence gives analysts and investors a clearer view of how upcoming catalysts could translate into enterprise growth.

Looking ahead, Soligenix’s combination of diversified programs, government-backed partnerships and an extended financial horizon presents a cohesive story of measured progress and high scientific potential. With cash resources projected to sustain operations through anticipated inflection points in 2026, the company is positioned to focus on what matters most: advancing late-stage assets toward market-ready outcomes.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://IBN.fm/SNGX

• A recent Simply Wall St analysis highlighted strong earnings growth and efficient profit reinvestment for SuperCom Ltd., with the company’s stock rising 22% over the past three months, reflecting renewed investor confidence.
• The company achieved 97% earnings growth year-on-year, far outpacing both industry and market averages, with five-year earnings growth standing at 45%, compared to 15% for the broader industry.
• SuperCom reinvests profits instead of paying dividends, channeling funds into its PureSecurity(TM) electronic monitoring platform and new market entries, allowing SuperCom’s return on equity (“ROE”) of 8.1% to align with industry norms while supporting consistent expansion.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has drawn positive attention from analysts at Simply Wall St, which noted the company’s consistent earnings growth and improving fundamentals amid a period of stock strength (https://ibn.fm/Z862K).

Over the past quarter, SuperCom’s shares have climbed by more than 20%, supported by operational gains and continued adoption of its technology in the U.S. and Europe. The analysis points to the company’s ability to translate reinvested profits into sustained income growth, a trend that has differentiated it within its sector.

Simply Wall St’s evaluation focused on return on equity (“ROE”) as a measure of management efficiency. ROE indicates how effectively a company converts shareholder equity into profit. SuperCom’s ROE stood at 8.1% for the 12 months to June 2025, based on net income of approximately $3.0 million and shareholders’ equity of $37 million. While this figure is modest, it is broadly in line with the industry average of 9.7%.

The report further underlines that SuperCom’s performance has been notable for its rapid earnings expansion. Over the past five years, the company’s net income grew 45%, triple the 15% growth rate seen across comparable industry peers. Over the most recent fiscal year, earnings increased by 97%, compared to 4% growth across the broader industry and 9% across the general market. This combination of moderate capital efficiency and strong reinvestment discipline has contributed to the company’s improving market profile.

According to the Simply Wall St report, SuperCom’s growth trajectory has been supported by its decision to reinvest all profits into operations rather than distribute dividends. This reinvestment strategy has allowed the company to strengthen its core technologies, expand its geographic reach, and secure a series of new contracts, particularly in the electronic monitoring (“EM”) sector.

While earnings growth is often linked to high ROE, SuperCom’s performance suggests additional drivers at play, notably strategic execution, low payout ratios, and focused investment in scalable technologies. The report notes that management decisions appear to have amplified the effects of modest equity returns by prioritizing growth and cost discipline.

SuperCom’s earnings momentum is closely tied to its expansion in public safety and offender monitoring solutions. The company’s flagship PureSecurity(TM) suite integrates GPS, RFID, and cloud-based monitoring into a modular platform for various law enforcement and correctional applications.

• PureMonitor(TM), a cloud-based software hub for real-time supervision.
• PureOne(TM), a one-piece GPS bracelet for continuous tracking indoors and outdoors.
• PureCom(TM), a radio frequency (“RF”) base station for house arrest programs.
• PureTag(TM), a compact RF bracelet compatible with other PureSecurity components.
• PureTrack(TM), a smartphone-based GPS tracking system paired with the PureTag solution.
• PureShield(TM) (U.S.) and PureProtect(TM) (EU), mobile apps that improve the safety of domestic violence victims through proximity alerts.
• PureBeacon(TM), an RF device for indoor surveillance in environments where GPS signals are limited.
• PureReader(TM), used for monitoring inmate movements within detention centers.

These systems are designed to provide courts and agencies with actionable real-time data, improving supervision outcomes and enhancing public safety. The company’s technology is already in use across the U.S. and Europe, including multi-year contracts in Sweden, Germany, and Romania, where legacy systems are being replaced by SuperCom’s cloud-based infrastructure.

SuperCom’s business model aligns with a growing global focus on rehabilitation-based justice systems and digital transformation in public safety management. Research supports the effectiveness of electronic monitoring:

• In Argentina, EM reduced one-year recidivism by 48% (Di Tella & Schargrodsky, 2013) (https://ibn.fm/oszmo).
• In Australia, it lowered two-year reoffending rates by 28% (Williams & Weatherburn, 2020) (https://ibn.fm/LBai9).
• In France, EM reduced five-year recidivism by 10% (Henneguelle et al., 2016) (https://ibn.fm/zvZbb).

These findings underline the social and economic value of monitoring solutions — reducing incarceration costs while supporting rehabilitation.

SuperCom’s stock performance over recent months may also reflect renewed confidence in its U.S. operations, where the company continues to secure new contracts through its PureSecurity(TM) reseller network. In recent announcements, SuperCom reported multiple state-level wins, including deployments in Virginia, Kentucky, and Utah, as part of a broader North American growth strategy.

The Simply Wall St review highlights SuperCom’s earnings growth far exceeding industry norms, indicating efficient use of reinvested capital. The Simply Wall St coverage underscores improving fundamentals, a strong earnings record and disciplined reinvestment strategy. With continued focus on reinvesting earnings, while strengthening its presence in key markets, SuperCom is viewed as well-positioned to maintain its growth momentum.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte(TM) (synthetic hypericin) and related therapies.
• These changes are timely given the complexities of CTCL and the evolving therapeutic landscape.
• The company’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight.

Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise and leadership at the center of its HyBryte(TM) development program (https://ibn.fm/ueKOC). This strategic move signals the company’s deepening commitment to advancing its pipeline agents in CTCL and aligning clinical strategy with evolving standards of care.

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte (synthetic hypericin) and related therapies; specifically, the updates include the addition of new members and the retirement of prior advisors. The company noted that the updated board reflects growing scientific insight into CTCL treatment pathways and is intended to enhance the translational and clinical strategic guidance for HyBryte’s potential regulatory and commercial trajectory.

“We are pleased to be able to attract such esteemed and enthusiastic professionals to participate as members of our Medical Advisory Board,” said Soligenix president and CEO Christopher J. Schaber. “Many of the MAB members have experience treating patients with HyBryte and have been invaluable to the program. We are excited to continue to work with them to facilitate the advancement of HyBryte to commercialization worldwide.” According to the company, the newly configured advisory board will provide counsel on pivotal trial design, regulatory engagement and potential strategic partnerships in CTCL.

These changes are timely given the complexities of CTCL and the evolving therapeutic landscape. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin and is characterized by malignant T-cells residing in the skin for prolonged periods. The condition can progress from patches and plaques to tumors, and in advanced stages may involve lymph nodes or internal organs.

According to the Lymphoma Research Foundation, around 3,000 new cases of CTCL are diagnosed in the U.S. annually, and the disease remains incurable (https://ibn.fm/op83a). Treatment options include skin-directed therapies, systemic agents, biologics and recently approved targeted therapies, but unmet needs persist, especially for relapsed or refractory disease and in patients who progress despite available options. The highly heterogeneous nature of CTCL and its variable course make clinical development particularly challenging.

In that context, the role of a strong and relevant Medical Advisory Board becomes crucial. Soligenix’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight. The updated advisory board is expected to advise on patient population definitions, endpoint selection, dose optimization, long-term follow-up strategies and potential label positioning. For HyBryte, which has already demonstrated positive results in its first Phase 3 clinical trial, having an advisory board closely aligned with specialist clinicians and thought leaders may accelerate registration pathways, refine patient-selection strategies and support market-access planning.

Moreover, the timing aligns with Soligenix’s broader pipeline strategy. The company has noted that HyBryte is a lead value driver, with its next expected inflection points including data read-out and regulatory engagement in the 2025–2026 timeframe (https://ibn.fm/84p9u). By updating its advisory board now, Soligenix is aligning its governance and clinical strategy ahead of those anticipated milestones, positioning itself for disciplined execution and clearer regulatory dialogue.

Experts in CTCL treatment emphasize the importance of strategic collaborations and advisory input in rare-disease trials. Given the low incidence of CTCL and diversity of disease presentation, engaging a board with recognized clinical experience in cutaneous lymphoma, dermatology-oncology interplay and regulatory mindset can enhance trial recruitment, endpoint relevance and payer discussions post approval. Soligenix’s updated board may also contribute insight into combinatorial strategies, development of biomarker-driven patient subgroups and incorporation of patient-reported outcomes, all of which are increasingly emphasized by regulatory authorities and payers in rare-disease drug development.

From an investor vantage point, this advisory board update signals that Soligenix is not only advancing its HyBryte therapy but also refining the infrastructure around it, an often underrated aspect of clinical-stage biotech execution. With an extended cash runway, thanks in part to a recent $7.5 million public offering (https://ibn.fm/QKXcv) and a refreshed advisory board guiding its CTCL strategy, the company looks to be better positioned as it moves forward.

The company’s update to its U.S. Medical Advisory Board for CTCL reflects strategic alignment with the complex and evolving CTCL therapeutic landscape. With HyBryte as a core value driver and a clinical development timetable that points into 2026, the company is actively preparing the frameworks, both scientific and regulatory, for advancement and potential commercialization. As CTCL remains an area of considerable unmet need, Soligenix’s refreshed advisory board may serve as a differentiator in successfully navigating that terrain.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://IBN.fm/SNGX

• The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”)
• Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug
• The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon

Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003.

The announcement occurred at the Australian Translational Breast Cancer Research Symposium (“ATBCR”).

Sapu-003 is the first IV Deciparticle(TM) formulation of Everolimus (Afinitor(R)), which is an mTOR inhibitor that’s widely used in oncology to treat various forms of cancer. While oral Everolimus (Afinitor(R)) is effective at treating breast cancer, neuroendocrine tumors, and renal cell carcinoma, broader use has been inhibited due to its low bioavailability and variable systemic exposure.

In contrast, Sapu-003 aims to offer much higher bioavailability, which will allow more of the drug to enter the patient’s system.

The Sapu-003 trial is being conducted in collaboration with the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon. These partnerships ensure that the clinical trial is executed precisely, aligns with regulations compliance, and to manage and monitor all aspects of the trial for favorable outcome.

This trial (ACTRN12625001083482) is open to leading oncology centers for enrollment. The eligible participants include both adults with advanced HR+/HER2– breast cancer and those with other mTOR-sensitive tumors that have already tried other standard therapies.

When speaking about Sapu-003 and the trial, CEO of Sapu Nano, Dr. Vuong Trieu said that “Sapu-003 represents a significant advancement in the delivery of mTOR-targeted therapies,”. He also added that “Through the combined expertise of SOCRU, Ingenū, and Medicilon, we are positioned to accelerate development and bring this next-generation treatment option to patients with advanced cancers.” 

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapeutics to help fight cancer and pediatric diseases with high unmet medical needs. Oncotelic leverages the portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications with 75 issued patents. The company also enhances its capabilities through strategic partnerships, licensing, and joint ventures — notably its 45% ownership of GMP Bio, led by Dr. Trieu, which is advancing complementary drug candidates that strengthen Oncotelic’s leadership in therapeutics.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

The Blockchain Futurist Conference Florida 2025 is preparing to ignite Miami this November 5–6, delivering a high-energy, future-forward experience where Web3, crypto, and AI collide. Now just days away, the event has officially released its full agenda, offering a first look at the groundbreaking conversations, powerhouse speakers and cultural moments set to define this year’s show.

Hosted at DAER inside the iconic Hard Rock Guitar Resort, the 2025 Futurist Conference marks the event’s first-ever U.S. edition and promises an immersive two-day lineup built for builders, innovators, investors, creators and future-thinkers shaping digital economies.

From the moment doors open on Day 1, attendees will move through a packed schedule across the Main Stage, Rooftop Stage and Argentum AI Stage, each programmed to spark ideas, expand networks and accelerate the next wave of industry breakthroughs.

Expect big-picture keynotes on AI regulation, tokenized economies, and global crypto adoption, followed by high-impact panels diving into real-world implementation: DeFi, stablecoins, on-chain identity, decentralized governance, and scaling crypto infrastructure. And yes, signature rooftop energy returns, delivering Miami vibes, skyline views and open-air conversations that fuel the best deal-flow and discoveries.

The second day pushes deeper into execution and strategy. Venture insights, startup showcases, and hands-on technical explorations give founders, developers and investors real pathways to build and deploy.

The Argentum AI Stage, anchored by the fifth-annual AI Futurist program, shines a spotlight on the intersection of AI and Web3, exploring decentralized AI systems, hybrid compute, next-gen token models and the future of intelligent autonomous networks.

Agenda Highlights

With the release of the official schedule, attendees can now explore cornerstone sessions including:

• The Future of Cross-Border Payments: How Blockchain and Digital Currencies Are Transforming Global Trade & Finance
• Stablecoins & Market Liquidity: Safety Net or Volatility Driver?
• DAOs & the Future of Governance: Rethinking Decision-Making in a Decentralized Era
• Beyond the Hype: NFTs and the Next Evolution of Digital Ownership

Explore the full schedule here: https://www.futuristconference.com/schedule

Combined with fireside chats, live demos, AI workshops and brand activations across two expo floors and 30+ VIP cabanas, Futurist Miami is engineered for discovery, access and acceleration.

True to the Futurist identity, this year’s programming blends cutting-edge industry content with cultural pulse and star presence. With celebrity-led discussions, creator-driven projects, and emerging tech talent on stage, the conference continues its role as a cultural bridge, where mainstream meets metaverse and influence meets innovation.

The Future Arrives in Miami

As the Miami tech scene continues to surge, Futurist 2025 lands at the perfect moment: when Web3 and AI are transitioning from theory to global impact, and the builders leading that shift are ready to share what comes next.

Whether you’re scaling a protocol, launching a startup, investing in the next wave or simply ready to learn from the leaders shaping tomorrow’s digital world, the only place to be this November is Blockchain Futurist Conference Florida 2025.

Bring your questions. Bring your curiosity. Bring your ambition. The future isn’t waiting, it’s being built at Blockchain Futurist.

For more information, visit www.FuturistConference.com.

This article has been disseminated on behalf of Trilogy Metals and may include a paid advertisement.

• Trilogy Metals CEO Tony Giardini discussed the Ambler Road, also known as the Ambler Access Project, that links the Dalton Highway to the Ambler Mining District.
• Interview touched on the granting of the road permits, what makes this part of Alaska so special, and the timeline of the work.
• Giardini also commented on the federal equity stake in Trilogy, upcoming key milestones for the company, and his thoughts on the most important metals for the economy and national security.

Tony Giardini, the CEO of Trilogy Metals (NYSE American: TMQ) (TSX: TMQ), a mineral exploration and development company, recently sat down for a chat about the Ambler Road with Rick Van Nieuwenhuyse, Chair of Valhalla Metals. 

The Ambler Road is a 211-mile industrial-use-only road connecting Alaska’s Dalton Highway to the Ambler Mining District. The road is a key piece of infrastructure that enables the exploration and development of the Ambler Mining District.

The conversation began with both executives talking about the history of the Ambler area and the efforts to secure road access. It then moved to the recent news of the federal government’s decision under Section 1106 of the Alaska National Interest Lands Conservation Act (“ANILCA”), which grants the permits for the Ambler Road.

This move by the U.S. administration unlocks one of the richest mineral districts in the country, which is home to the Arctic and Bornite deposits. President Trump also directed all relevant agencies to promptly grant and finalize all permits needed to ensure the area may be accessed for economic, mining, industrial, and commercial purposes.

In regards to the Presidential approval, Giardini called it more than a permit and said it’s really a legislatively backed pathway to unlock the district. Giardini continued to speak on how this area of Alaska is known for exceptional metal grades and the diversity of the different metals there, such as copper, zinc, cobalt, and precious metals.

Later in the chat, Giardini was asked about the Department of War’s 10% equity investment in Trilogy. He said that it was massive for not only the company, but also the district in general, as federal involvement brings validation to the importance of the project, creates stability, mitigates long-term risks, and shows how important these metals are to both the economy and national security.

Giardini was also asked about the key upcoming milestones for Trilogy, and he responded by saying that these include finalizing the road development plan, securing funding for the initial construction, and resuming project activities at the Ambler Mining District

When asked about the current and projected market dynamics, Giardini highlighted copper’s role as the backbone of energy infrastructure. He also added that cobalt and zinc are going to be crucial for batteries and storage technologies.

The conversation ends with Giardini stating he’s excited about the exploration potential of the district, and that he looks forward to seeing the road advance in a meaningful fashion.

About Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)

Trilogy Metals Inc. is a mineral exploration and development company, with a focus on advancing critical mineral assets in Alaska. The company has the vision of responsibly developing the Ambler Mining District into a source of important minerals, while also delivering value to shareholders and local communities.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ

• BluSky AI’s modular data centers will reflect the next generation of AI infrastructure, created to quickly meet the increasing demand for high-performance computing (“HPC”) and AI
• The firm’s SkyMod(TM) units will soon help deliver energy-efficient, scalable infrastructure capable of powering ML, AI, and data-intensive workloads
• By making efforts to solve the global need for computing power, the company is strategically positioning itself as a future leader in the AI revolution

While the tech industry has become fond of the use of large data centers, they now risk becoming outdated before being fully completed. More specifically, today’s evolving requirements of AI make it challenging for them to keep up. BluSky AI (OTC: BSAI) is reimagining the digital backbone of the AI era with an efficient, infrastructure-centered approach. With headquarters in Salt Lake City, Utah, the company is preparing to lead the future of the AI infrastructure through a new Neocloud network, to be hosted by its web of SkyMod(TM) data centers, called AI Factories. These technologies are proprietary to BSAI. The custom-built solution will support the increasing computational needs of machine learning, AI, and high-performance computing applications (ibn.fm/B3sRR).

With global AI ambitions severely impacted by limitations in access to compute power, the firm will soon provide flexible, fast, and lasting solutions. BluSky AI’s Neocloud, through the SkyMod series of prefabricated data centers, such as SkyMod(TM) XL and SkyMod(TM) One, will supply a ready-to-use network that will meet the compute-intensive needs of AI training and language-learning models. Every SkyMod is designed and built off-site, then deployed for use on either client facilities or powered land leased or owned by BlueSky AI, significantly reducing infrastructure and time-to-compute costs.

Within the past two quarters of 2025, BluSky AI has achieved major milestones to put them in a great position to leverage its network. The company announced six new sites spanning 130 acres and 85 MW of power across Utah, Colorado, Arizona and Nevada. In pursuit of a future NASDAQ listing, partnerships with Lilac to distribute a GPU marketplace partnership, and the re-engineering of a major chip manufacturer’s GPU to  fit for the SkyMod Factories, further expand BSAI’s ecosystem.

Building on its record of innovation, BluSky AI recently received an annual innovation achievement award from Utah Business in the manufacturing and development category. The firm’s leadership has broad experience in finance, telecoms, and technology. Dan Gay, the COO, has decades of operational leadership in the energy and technology fields, supporting the firm’s growing market partnership and expansion. CEO Trent D’Ambrosio is experienced in energy integration strategy and global telecom innovation. Julien Bedard, the CTO, comes with experience in cybersecurity, cloud architecture, and blockchain infrastructure.

With the rapid growth of AI adoption globally, the need for efficient, scalable compute power is on the rise. The global data center market is expected to reach $652 billion by 2030 from $347.6 billion in 2024, catalyzed by generative AI, machine learning, and Internet of Things adoption. BluSky AI’s GPU-centric design and rapid-deployment model give it strong leverage in the global market.

For more information, visit the company’s website at BluSkyAIDataCenters.com.

NOTE TO INVESTORS: The latest news and updates relating to BSAI are available in the company’s newsroom at https://ibn.fm/BSAI

• Nightfood Holdings Inc. recently announced that the company is generating approximately $10 million in annual revenue
• The revenue comes from the company’s diversified portfolio of AI robotics and hospitality assets
• NGTF also recently announced that the company’s expanding the robotic live pilot programs beyond the hospitality industry

Nightfood Holdings (OTCQB: NGTF), dba TechForce Robotics, an AI robotics company, recently announced that it is generating around $10 million in annualized revenue, a result of its diverse portfolio of income-producing hospitality and robotics assets. The company’s acquisition strategy is central to this growth, highlighted by its recent purchase of the 120-room Hilton Garden Inn in Rancho Mirage for approximately $52.8 million. This marks its fifth acquisition in under two years as it continues to build an integrated robotics ecosystem that combines real estate with advanced automation.

The company has evolved into a revenue-generating high-growth business built on not only recent hotel acquisitions, but also an expanding Robotics-as-a-Service (“RaaS”) platform. NGTF has also integrated automation into the hotels it owns to not only reduce costs, boost efficiency, and improve guest experience, but also to optimize, validate, and scale the technology.

Speaking about the milestone, CEO of NGTF, Jimmy Chan, stated that “Reaching the $10 million annualized revenue mark represents a defining milestone and validates our integrated growth model,”.

He added that “Our hotel acquisitions and RaaS platform are working in tandem to deliver measurable results and create long-term shareholder value. We remain focused on executing our roadmap and scaling our presence in the rapidly evolving hospitality automation market.” 

NGTF is also planning to uplist to a national exchange and is aligned to meet uplisting requirements thanks to the high-margin potential of the company’s AI robotics, along with recurring revenue from the hotels.

While the focus has been on the hospitality industry, NGTF also recently announced that the company is expanding the robotic live pilot programs beyond hospitality into a variety of other spaces. This includes casinos, stadiums, convention centers, shopping malls, schools, and assisted living facilities.

These pilot programs feature the company’s robots helping with various tasks like handling laundry, waste management, and cooking. This step is a major milestone for the company as it transitions from development to deployment.

Ried Floco, President of NGTF, said that “By validating performance across multiple real-world settings, we’re proving that our technology is adaptable, reliable, and ready for mass deployment.” 

When speaking about the response to the pilots, Chan added that “The data has been overwhelmingly positive, showing measurable operational efficiencies and strong user acceptance. Each pilot provides valuable insights that we’re rapidly implementing as we scale production to meet growing demand.” 

About Nightfood Holdings Inc. (OTCQB: NGTF)

Nightfood Holdings Inc. (OTCQB: NGTF), doing business as TechForce Robotics, is an emerging robotics company that is developing and deploying AI-powered automation across a variety of industries. It has the aim of delivering scalable robots that boost efficiency, improve safety, and streamline operations.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

• Strawberry Fields REIT, Inc., a self-administered real estate investment trust, posted its AFFO for Q2 2025 at $18.4 million, up from $14.3 million during the same period in 2024
• From 33 Skilled Nursing Facilities (“SNF”) in 2015, the Company has grown its portfolio to 142 healthcare facilities, totaling over 15,500 licensed beds across 10 states in the U.S.
• Founder, CEO, and Chairman, Moishe Gubin, built Strawberry Fields with an operator point of view, while focusing on the real estate side of things
• By combining a unique knowledge of the healthcare and real estate industries, the Company positioned itself to carve out a growing market share and assert its place as a leader in the industry
• The Company is set to announce its Q3 financial results on November 6 after the close of market and hold its quarterly earnings call on November 7

Strawberry Fields REIT (NYSE: AMERICAN: STRW) (the “Company”), a self-administered real estate investment trust engaged in the ownership, acquisition, and leasing of skilled nursing and specific other healthcare-related properties, posted $18.4 million in Adjusted Funds From Operations (“AFFO”) for Q2 2025, a significant growth from $14.3 million during the same period in 2024. While announcing the milestone, the Company’s Chairman and CEO, Moishe Gubin, lauded the benefits of its master lease structure and acknowledged the Company’s strongest quarter since its founding.

“I am pleased to be reporting a very strong second quarter. Our earnings are the strongest they have been since the Company was founded 10 years ago,” he noted.

Strawberry Fields has experienced consistent growth since its founding. This growth can be attributed mainly to its management, led by Moishe Gubin, the Chairman, CEO, and Founder, along with Jefferey Bajtner, the Chief Investment Officer, and Greg Flamion, the Chief Financial Officer. Today, the Company directly impacts tens of thousands of lives across the United States. 

Beginning in 2003, Gubin and his operating partner, Michael Blisko, the CEO of Infinity Health Care Management, set out to acquire and operate Skilled Nursing Facility (“SNF”) properties. Between 2003 and 2014, they grew the portfolio to 33 facilities in Illinois and Indiana. In 2015, Gubin founded Strawberry Fields with the bold ambition to aggressively expand across the United States.

“We spun off Strawberry Fields REIT in 2015 with 33 facilities, in Indiana and Illinois. Our goal at the time was to diversify operators and locations,” Gubin noted (https://ibn.fm/02tj8).

By combining a unique knowledge of the healthcare and real estate industries, the Company, under the leadership of Gubin, was well positioned to carve out market share. To this day, it targets high-quality healthcare operating companies in the Skilled Nursing and Acute sectors and has built a thriving network of carefully selected facilities. In addition, its deep ties with industry leaders position Strawberry Fields strategically to partner with future-focused operators, a factor that sets it apart from other players. 

Since 2015, the focus has been strictly on the real estate side, acquiring and leasing, while letting others handle operations. Yet, having worked in the industry, Mr. Gubin understood what went into the business, what to watch out for, and what he could do differently to stand out from the rest of the market players.

“Since I actually worked at the original nursing homes, I started this Company with an operator point of view. The Company evaluates deals as if we were going to be operating it: what deal would we make, how would we buy, what kind of services would we provide? Then we find a tenant that has a similar point of view,” he added (https://ibn.fm/eSl2V).

The Company now holds long-term leasehold interests in 142 healthcare facilities, totaling over 15,500 licensed beds across ten states in the United States. In addition, given its due diligence and pragmatism in selecting tenants and partners for its projects, the Company has never missed a single rent payment over the past 10 years.

“We’ve collected 100% of our rents and haven’t written off a bad loan. I think our stock is perfect for a more conservative investment with a better yield,” Gubin noted (https://ibn.fm/eSl2V).

Going forward, Strawberry Fields is on an aggressive market expansion plan. Recently, the Company acquired nine SNFs in Missouri, totaling 686 beds for $59 million. It also acquired an 80-bed SNF in Oklahoma for $4.25 million and a 124-bed facility comprising 108 skilled nursing beds and 16 assisted living beds near Poplar Bluff, Missouri (https://ibn.fm/hAWOG). Gubin has noted that these expansions demonstrate the Company’s financial discipline and consistency, while also offering a glimpse into its future.

The Company is set to release its Q3 2025 financial results on November 6 after the close of market, with experts optimistic about the Company maintaining its disciplined investment strategy following Q2 performance. On November 7, 2025, at 11:00 a.m. Eastern Time, the Company’s management team will be holding its quarterly conference call/webcast to discuss the 2025 third quarter results and invites current and prospective investors to join. A live webcast of the conference call can also be accessed, on a listen-only basis, using this link (https://ibn.fm/Iizh9).

For Company information, visit the Company’s website at www.StrawberryFieldsREIT.com.

NOTE TO INVESTORS: The latest news and updates relating to STRW are available in the Company’s newsroom at https://ibn.fm/STRW

• The ‘Box Cleaner,’ an autonomous industrial robotics cleaning system, will be trialed at Helsingborg Port in Sweden, one of the most advanced and sustainability-focused ports in Scandinavia.
• The robot operates autonomously for extended periods, leveraging AI-driven navigation and edge-computing to optimize energy and water usage.
• Built on Micropolis’ M2 platform, the system will collect operational data during trials to refine performance ahead of commercial rollout in Europe and the Middle East.
• The project supports sustainability goals by reducing manual labor, emissions, and resource consumption in port and industrial cleaning operations.
• The collaboration expands Micropolis’ reach beyond security and law enforcement robotics into broader industrial and infrastructure applications.

Micropolis (NYSE American: MCRP), a pioneer in unmanned ground vehicles (“UGVs”) and AI-driven security solutions, announced that it has entered into an agreement with Helsingborgs Hamn AB, operator of the Port of Helsingborg in Sweden, and MCS Robotics AB, a Swedish robotics firm, to jointly develop and test the Box Cleaner, an autonomous robotic cleaning system designed for port and industrial environments (https://ibn.fm/HJXkz).

The Box Cleaner is built on Micropolis’ proprietary M2 platform, integrating the company’s AI navigation software, edge-computing architecture, and autonomous control systems. Designed for large outdoor and semi-industrial environments, the robot performs precision cleaning operations over extended periods without human intervention.

The platform’s capabilities include adaptive route planning, object recognition, and dynamic resource optimization, allowing the robot to minimize water and power consumption while maintaining consistent operational output. The company expects the trial to yield detailed operational data for refining performance metrics ahead of broader commercialization.

The pilot program will take place at Helsingborgs Hamn, one of Sweden’s busiest ports and a recognized hub for innovation in logistics and sustainability. The trial will test the Box Cleaner in real-world conditions: on container surfaces, paved storage areas, and heavy-use zones, to evaluate how the system performs across varying weather, traffic, and debris conditions.

For Helsingborgs Hamn, the collaboration fits into a long-term plan to digitize port operations and reduce the environmental footprint of logistical infrastructure. The port has been an early adopter of green initiatives, including automation and electrification of cargo handling.

Micropolis CEO Fareed Aljawhari emphasized the importance of cross-border cooperation in developing and deploying practical robotics solutions. “This partnership with two renowned Swedish companies in the robotics and marine logistics space demonstrates how international collaboration can accelerate the deployment of practical robotic solutions,” Aljawhari said, adding that “Working alongside Helsingborgs Hamn AB and MCS Robotics allows us to validate our technologies in one of Europe’s leading ports, while aligning with the global shift toward smart, sustainable operations.”

The project’s collaborative model, uniting AI development, robotics engineering, and operational testing, reflects a growing trend in industrial automation. Robotics manufacturers are increasingly working directly with end users in logistics and transport to ensure that new systems meet the operational and regulatory demands of their environments.

The Box Cleaner project marks another step in Micropolis’ diversification strategy. While the company is widely known for its AI-driven autonomous patrol vehicles deployed in security and law enforcement, most recently in partnership with Dubai Police, its modular technology is designed to adapt across multiple industries.

Micropolis’ underlying software and hardware architecture are built to support various applications, including urban logistics, infrastructure management, and environmental services. By entering the industrial automation sector, the company broadens its commercial base and demonstrates the scalability of its autonomous systems.

Furthermore, the collaboration with Helsingborgs Hamn and MCS Robotics reinforces Micropolis’ growing international presence. With operations and partnerships now spanning the Middle East, Europe, and Asia, the company continues to demonstrate its adaptability and technical credibility in multiple sectors.

For more information, visit the company’s website at www.Micropolis.ai.

NOTE TO INVESTORS: The latest news and updates relating to MCRP are available in the company’s newsroom at https://ibn.fm/MCRP